These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [New treatment options for primary immune thrombocytopenia].
    Author: Gudbrandsdottir S, Frederiksen H, Birgens HS, Nielsen CH, Nielsen OJ, Stentoft J, Hasselbalch HC.
    Journal: Ugeskr Laeger; 2011 Jan 24; 173(4):271-4. PubMed ID: 21262171.
    Abstract:
    Primary immune thrombocytopenia (ITP)--formerly known as idiopathic thrombocytopenic purpura--is an autoimmune disorder characterized by immune mediated thrombocytopenia. The aetiology of ITP remains unknown, but studies have shown that multiple immunological mechanisms are involved in the pathogenesis of ITP. This article aims to provide an overview of current treatment options, with particular emphasis on new biological therapies: rituximab, a monoclonal anti-CD20 antibody, and the thrombopoietin receptor agonists romiplostim and eltrombopag.
    [Abstract] [Full Text] [Related] [New Search]